Pulse Biosciences, Inc.

PLSE

$53.35

-2.49%

2026-09-04 12:56:55 EDT-$1.36

Healthcare

Medical - Instruments & Supplies

NASDAQ

Active Trading

Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform ...

Recent News of PLSE

Business Wire7/30/2026Neutral

Pulse Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to participate in the upcoming Canaccord Genuity 46th Annual Growth Conference in Boston, MA. Pulse Biosciences' Management is scheduled to present on Tuesday, August 11, at 2:30 pm ET. A live and recorded webcast of the fireside chat will be available on the “Events Calendar and Presenta.

Business Wire7/29/2026Neutral

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the NANOPULSE-AF Study has surpassed its enrollment midpoint after commencing the study in April 2026. “We are very pleased by the strong enrollment trajectory in the NANOPULSE-AF study. Reaching this midpoint milestone so quickly reflects the enthusiasm of our investigational sites for th.

Business Wire7/21/2026Neutral

Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates and financial results for the second quarter 2026 after market close on Thursday, August 6, 2026. Company management will host a corresponding conference call to discuss business updates beginning at 1:30pm PT / 4:30pm ET.Investors interested in listening to the c.

Business Wire7/15/2026Neutral

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued.

Seeking Alpha6/10/2026Neutral